PDS Biotech CEO to Present at H.C. Wainwright Conference
PRINCETON, N.J. – PDS Biotechnology Corporation (Nasdaq: PDSB), a pioneering force in immunotherapy, is preparing for a notable presentation at the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. Frank Bedu-Addo, PhD, who serves as the Company’s President and CEO, will be leading the discussion, which will highlight groundbreaking developments in cancer treatment and vaccine innovation.
Details of the Conference Presentation
Here are the specifics regarding Dr. Bedu-Addo's presentation:
- Event: H.C. Wainwright 26th Annual Global Investment Conference
- Date: September 10, 2024
- Time: 2:00 - 2:30 PM ET
For those interested in attending, registration for in-person participation is available. Additionally, the presentation will be accessible for on-demand viewing beginning September 10, 2024, at 2:00 PM ET.
About PDS Biotechnology
PDS Biotechnology is at the forefront of transforming cancer treatment through cutting-edge immunotherapy. The company is dedicated to improving the immune response against both infections and tumors. In 2024, PDS Biotech plans to launch a pivotal clinical trial for its flagship program aimed at advanced HPV16-positive head and neck squamous cell cancers. This groundbreaking initiative combines its investigational immunotherapy, Versamune HPV, with immune checkpoint inhibitors to enhance treatment effectiveness in difficult cancer cases.
Innovations and Future Aspirations
The upcoming trial represents just one part of PDS Biotech’s comprehensive strategy, which also includes the development of a combination therapy featuring its IL-12 fused antibody drug conjugate, PDS01ADC. As the field of cancer therapies continues to evolve, PDS Biotech is dedicated to remaining at the cutting edge, ensuring that new treatment options are accessible to patients in need.
Contact and Media Inquiries
For additional information, PDS Biotech has designated contacts for investor and media relations:
Investor Contact:
Mike Moyer
LifeSci Advisors
Phone: +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com
Media Contact:
Gina Mangiaracina
6 Degrees
Phone: +1 (917) 797-7904
Email: gmangiaracina@6degreespr.com
Frequently Asked Questions
What is PDS Biotech's primary focus?
PDS Biotech is primarily focused on immunotherapy for cancer treatment and the development of vaccines for infectious diseases.
When will the CEO present at the conference?
The CEO's presentation is set for September 10, 2024, from 2:00 to 2:30 PM ET.
How does PDS Biotech plan to advance cancer treatment?
The company intends to initiate a pivotal clinical trial targeting HPV16-positive cancers to advance its leading program.
What is Versamune?
Versamune is an investigational immunotherapy developed by PDS Biotech, designed to boost the immune system's capacity to fight cancer.
How can I access the presentation after the event?
The presentation will be available for on-demand viewing on PDS Biotech’s website following the conclusion of the event.